Comment on Avalanche Journal: Colorado needs its value-rebuilding factory to produce the next Jonathan Drouin

Nuggets point guard Reggie Jackson is picking up his $5.25 million player option for the 2024-25 season as expected, a league source confirmed to The Denver Post. Jackson, 34, will return for the second and final year of his contract. He came to Denver in February 2023 after reaching a contract buyout with the Charlotte Hornets and won his first career NBA championship five months later as a reserve for his hometown team.

During the Colorado Rapids’ 4-1 win over CF Montréal on Saturday, multiple signs and tifos backing defender Moïse Bombito were scattered around the stands, particularly behind the south goal, where the Centennial 38 supporters group is located. The show of support for Bombito, who is Black and also plays for the Canadian men’s national team, came after he became the target of racist harassment on social media last week following a Copa America match last Thursday against Argentina. Bombito tackled Inter Miami star and World Cup champion Lionel Messi during that match while tracking back to stop an Argentinian attack on goal.

Sean Keeler: The joke’s on Joker. And us. Trust the basketball gods to give Denver one of the most watered-down draft classes in modern NBA history in a summer when the Nuggets absolutely need to find some diamonds among all that rough. The upside? We’re losing sleep over tweaks, nips and tucks.

Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks Yahoo FinanceLilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution | Eli Lilly and Company Investors | Eli Lilly and CompanyAmid duel with Novo's Wegovy, Lilly's Zepbound homes in on potential FDA sleep apnea nod FiercePharmaWeight-Loss Drug Zepbound Offers a New Way to Treat Sleep Apnea The New York Times

A ketamine pill may help hard-to-treat depression with fewer side effects, early research suggests CNNExtended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial Nature.comSlow-release ketamine tablets help prevent depression relapses, UK trial finds The GuardianElon Musk-backed ketamine therapy offers hope to patients with severe depression where other medication fails Daily MailKetamine tablets help reduce side-effects in depression sufferers Financial Times

Young gay Latinos see a rising share of new HIV cases, leading to a call for targeted funding The Associated PressView Full Coverage on Google News